0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment landscape of relapsed/refractory multiple myeloma. The current Food and Drug Administration approved CAR T cell therapies idecabtagene vicleucel and ciltacabtagene autoleucel both target B cell maturation antigen (BCMA), which is expressed on the surface of malignant plasma cells. Despite deep initial responses in most patients, relapse after anti-BCMA CAR T cell therapy is common. Investigations of acquired resistance to anti-BCMA CAR T cell therapy are underway. Meanwhile, other viable antigenic targets are being pursued, including G protein-coupled receptor class C group 5 member D (GPRC5D), signaling lymphocytic activation molecule family member 7 (SLAMF7), and CD38, among others. CAR T cells targeting these antigens, alone or in combination with anti-BCMA approaches, appear to be highly promising as they move from preclinical studies to early phase clinical trials. This review summarizes the current data with novel CAR T cell targets beyond BCMA that have the potential to enter the treatment landscape in the near future.

          Related collections

          Most cited references156

          • Record: found
          • Abstract: not found
          • Article: not found

          Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            An anatomically comprehensive atlas of the adult human brain transcriptome.

            Neuroanatomically precise, genome-wide maps of transcript distributions are critical resources to complement genomic sequence data and to correlate functional and genetic brain architecture. Here we describe the generation and analysis of a transcriptional atlas of the adult human brain, comprising extensive histological analysis and comprehensive microarray profiling of ∼900 neuroanatomically precise subdivisions in two individuals. Transcriptional regulation varies enormously by anatomical location, with different regions and their constituent cell types displaying robust molecular signatures that are highly conserved between individuals. Analysis of differential gene expression and gene co-expression relationships demonstrates that brain-wide variation strongly reflects the distributions of major cell classes such as neurons, oligodendrocytes, astrocytes and microglia. Local neighbourhood relationships between fine anatomical subdivisions are associated with discrete neuronal subtypes and genes involved with synaptic transmission. The neocortex displays a relatively homogeneous transcriptional pattern, but with distinct features associated selectively with primary sensorimotor cortices and with enriched frontal lobe expression. Notably, the spatial topography of the neocortex is strongly reflected in its molecular topography-the closer two cortical regions, the more similar their transcriptomes. This freely accessible online data resource forms a high-resolution transcriptional baseline for neurogenetic studies of normal and abnormal human brain function.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

              Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA), has potential for the treatment of multiple myeloma.
                Bookmark

                Author and article information

                Contributors
                URI : https://loop.frontiersin.org/people/1836246Role: Role:
                Role: Role:
                Role: Role:
                Journal
                Front Oncol
                Front Oncol
                Front. Oncol.
                Frontiers in Oncology
                Frontiers Media S.A.
                2234-943X
                10 May 2024
                2024
                : 14
                : 1398902
                Affiliations
                [1] Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY, United States
                Author notes

                Edited by: Saad Zafar Usmani, Levine Cancer Institute, United States

                Reviewed by: Sanjay De Mel, National University Cancer Institute, Singapore

                Francesca Cottini, The Ohio State University, United States

                *Correspondence: Sridevi Rajeeve, rajeeves@ 123456mskcc.org
                Article
                10.3389/fonc.2024.1398902
                11116580
                3da92d00-c6f6-4fe2-b249-124efbe5575b
                Copyright © 2024 Miller, Hashmi and Rajeeve

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 11 March 2024
                : 24 April 2024
                Page count
                Figures: 1, Tables: 3, Equations: 0, References: 157, Pages: 13, Words: 6505
                Funding
                The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.
                Categories
                Oncology
                Review
                Custom metadata
                Hematologic Malignancies

                Oncology & Radiotherapy
                multiple myeloma,car t cell therapy,chimeric antigen receptor,non-bcma,immunotherapy

                Comments

                Comment on this article